Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

FibroGen

DB:1FG
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1FG
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • FibroGen has significant price volatility in the past 3 months.
1FG Share Price and Events
7 Day Returns
3.8%
DB:1FG
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-33.2%
DB:1FG
-7.4%
DE Biotechs
-14.2%
DE Market
1FG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
FibroGen (1FG) 3.8% -4.4% -17.9% -33.2% 36.9% 12.2%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 1FG underperformed the Biotechs industry which returned -7.4% over the past year.
  • 1FG underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
1FG
Industry
5yr Volatility vs Market
Related Companies

1FG Value

 Is FibroGen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of FibroGen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for FibroGen.

DB:1FG Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1FG
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (2.34%))
1.045
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.045 * 5.44%)
5.3%

Discounted Cash Flow Calculation for DB:1FG using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for FibroGen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:1FG DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.3%)
2020 3.00 Analyst x1 2.85
2021 86.61 Analyst x2 78.11
2022 237.05 Analyst x2 203.05
2023 514.76 Analyst x2 418.76
2024 865.61 Analyst x2 668.75
2025 1,147.36 Est @ 32.55% 841.84
2026 1,407.43 Est @ 22.67% 980.73
2027 1,629.11 Est @ 15.75% 1,078.10
2028 1,806.82 Est @ 10.91% 1,135.56
2029 1,942.67 Est @ 7.52% 1,159.54
Present value of next 10 years cash flows $6,567.00
DB:1FG DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $1,942.67 × (1 + -0.39%) ÷ (5.3% – -0.39%)
$34,033.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $34,033.20 ÷ (1 + 5.3%)10
$20,313.68
DB:1FG Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $6,567.00 + $20,313.68
$26,880.68
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $26,880.68 / 88.00
$305.46
DB:1FG Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1FG represents 0.88545x of NasdaqGS:FGEN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88545x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 305.46 x 0.88545
€270.47
Value per share (EUR) From above. €270.47
Current discount Discount to share price of €31.15
= -1 x (€31.15 - €270.47) / €270.47
88.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price FibroGen is available for.
Intrinsic value
>50%
Share price is €31.15 vs Future cash flow value of €270.47
Current Discount Checks
For FibroGen to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • FibroGen's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • FibroGen's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for FibroGen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are FibroGen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1FG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.89
NasdaqGS:FGEN Share Price ** NasdaqGS (2020-04-08) in USD $35.18
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of FibroGen.

DB:1FG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FGEN Share Price ÷ EPS (both in USD)

= 35.18 ÷ -0.89

-39.6x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FibroGen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • FibroGen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does FibroGen's expected growth come at a high price?
Raw Data
DB:1FG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -39.6x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
54.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for FibroGen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on FibroGen's assets?
Raw Data
DB:1FG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.89
NasdaqGS:FGEN Share Price * NasdaqGS (2020-04-08) in USD $35.18
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:1FG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FGEN Share Price ÷ Book Value per Share (both in USD)

= 35.18 ÷ 5.89

5.97x

* Primary Listing of FibroGen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FibroGen is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess FibroGen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. FibroGen has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1FG Future Performance

 How is FibroGen expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
54.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is FibroGen expected to grow at an attractive rate?
  • FibroGen's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • FibroGen's earnings growth is expected to exceed the Germany market average.
  • FibroGen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1FG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1FG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 54.2%
DB:1FG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 20.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1FG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1FG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 712 786 472 2
2023-12-31 704 548 326 4
2022-12-31 436 327 -4 6
2021-12-31 369 99 -54 7
2020-12-31 323 229 -70 7
2020-04-08
DB:1FG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 257 -79 -77
2019-09-30 357 -51 42
2019-06-30 353 -15 49
2019-03-31 205 -22 -90
2018-12-31 213 -76 -86
2018-09-30 136 -60 -141
2018-06-30 147 -87 -123
2018-03-31 133 -71 -132
2017-12-31 131 -67 -121
2017-09-30 132 -84 -121
2017-06-30 122 -67 -121
2017-03-31 181 -3 -64

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • FibroGen's earnings are expected to grow significantly at over 20% yearly.
  • FibroGen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1FG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from FibroGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1FG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.70 4.70 4.70 1.00
2023-12-31 3.39 5.60 2.06 3.00
2022-12-31 -0.08 1.90 -1.68 4.00
2021-12-31 -0.61 0.36 -2.32 5.00
2020-12-31 -0.78 -0.16 -2.04 5.00
2020-04-08
DB:1FG Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.89
2019-09-30 0.49
2019-06-30 0.57
2019-03-31 -1.07
2018-12-31 -1.03
2018-09-30 -1.69
2018-06-30 -1.52
2018-03-31 -1.69
2017-12-31 -1.66
2017-09-30 -1.77
2017-06-30 -1.86
2017-03-31 -1.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if FibroGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess FibroGen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
FibroGen has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1FG Past Performance

  How has FibroGen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare FibroGen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • FibroGen does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare FibroGen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare FibroGen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
FibroGen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from FibroGen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1FG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 256.58 -76.97 135.48
2019-09-30 356.66 42.11 102.62
2019-06-30 352.51 48.99 82.16
2019-03-31 204.90 -90.44 70.47
2018-12-31 212.96 -86.42 63.81
2018-09-30 135.64 -141.27 59.81
2018-06-30 147.16 -123.17 57.41
2018-03-31 133.48 -131.66 55.78
2017-12-31 131.00 -120.88 51.76
2017-09-30 132.17 -120.98 50.49
2017-06-30 121.72 -120.68 49.19
2017-03-31 180.74 -64.45 46.14
2016-12-31 183.19 -58.07 46.03
2016-09-30 172.11 -79.05 46.41
2016-06-30 161.54 -99.99 46.00
2016-03-31 192.81 -67.25 45.30
2015-12-31 180.83 -85.78 44.36
2015-09-30 172.49 -84.97 44.22
2015-06-30 166.62 -79.41 43.12
2015-03-31 136.02 -97.60 40.96
2014-12-31 137.60 -59.50 36.91
2014-09-30 133.89 -24.47 32.00
2014-06-30 191.47 43.12 28.75
2014-03-31 117.21 -5.04 26.39
2013-12-31 102.17 -14.94 24.41

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if FibroGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if FibroGen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if FibroGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess FibroGen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
FibroGen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1FG Health

 How is FibroGen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up FibroGen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • FibroGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • FibroGen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of FibroGen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 41.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from FibroGen Company Filings, last reported 3 months ago.

DB:1FG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 535.41 16.78 533.76
2019-09-30 613.72 16.26 628.63
2019-06-30 648.30 16.85 660.76
2019-03-31 508.49 16.55 565.40
2018-12-31 528.47 16.80 621.40
2018-09-30 490.58 16.95 652.73
2018-06-30 514.80 16.98 671.90
2018-03-31 518.79 17.82 703.77
2017-12-31 547.74 17.84 735.72
2017-09-30 590.77 16.92 729.97
2017-06-30 249.37 16.28 359.40
2017-03-31 150.97 15.15 243.42
2016-12-31 175.11 14.85 253.18
2016-09-30 197.62 15.74 241.81
2016-06-30 212.38 15.52 230.52
2016-03-31 176.22 15.79 173.41
2015-12-31 196.83 15.09 181.17
2015-09-30 236.56 15.43 221.52
2015-06-30 272.89 15.19 248.67
2015-03-31 203.89 14.77 142.69
2014-12-31 240.68 16.47 179.82
2014-09-30 109.65 17.09 175.50
2014-06-30 139.87 18.89 202.09
2014-03-31 91.67 18.34 109.59
2013-12-31 107.60 18.86 122.81
  • FibroGen's level of debt (3.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (6.7% vs 3.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • FibroGen has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if FibroGen has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess FibroGen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. FibroGen has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1FG Dividends

 What is FibroGen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from FibroGen dividends. Estimated to be 0% next year.
If you bought €2,000 of FibroGen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate FibroGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate FibroGen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1FG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1FG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as FibroGen has not reported any payouts.
  • Unable to verify if FibroGen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of FibroGen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as FibroGen has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of FibroGen's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess FibroGen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can FibroGen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. FibroGen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1FG Management

 What is the CEO of FibroGen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Enrique Conterno
AGE 52
TENURE AS CEO 0.3 years
CEO Bio

Mr. Enrique A. Conterno is the Chief Executive Officer and Director at FibroGen, Inc. since January 6, 2020. He served as President of Lilly USA from January 2017 to 2019. Mr. Conterno served as President of Lilly Diabetes at Eli Lilly & Company since November 1, 2009 until December 31, 2019 and served as its Senior Vice President since November 2009 until December 31, 2019. Mr. Conterno served as the Head of the diabetes business unit at Eli Lilly & Co. since November 1, 2009. He served as Leader of Diabetes Business Unit at Eli Lilly & Co. since November 1, 2009. He served as Senior Vice President of Health Care Professional Markets at Lilly in the U.S. since June 2008. Mr. Conterno has more than 16 years of proven results and strong leadership. He served as Vice President for Health Care Professional Markets of Eli Lilly & Co. since May 2008. He led all Lilly USA efforts aimed at health care professionals and was also responsible for therapeutic and the neuroscience, diabetes and osteoporosis brands. He served as Vice President of the U.S. Neuroscience Business of Lilly. Mr. Conterno joined Lilly as a Sales Representative in 1992. From 1993 to 1995, he served as Financial Analyst, Marketing Associate and Business Development Manager. He served as Sales and Marketing Director for Lilly's Peru affiliate since 1996. He served as Sales and Marketing Director at Lilly Brazil since 1998. Mr. Conterno served as Executive Director of Marketing for Lilly's Intercontinental Region (all international markets except for Europe and Japan) and Japan since 2000. He served as General Manager of Lilly Mexico since 2003 and Vice President of Lilly's Neuroscience Business Unit in the U.S. since 2006. Mr. Conterno received a Master's of Business Administration degree from Duke University in 1992. He also holds a Bachelor's degree in Mechanical Engineering from Case Western Reserve University in 1989.

CEO Compensation
  • Insufficient data for Enrique to compare compensation growth.
  • Insufficient data for Enrique to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the FibroGen management team in years:

4
Average Tenure
57
Average Age
  • The tenure for the FibroGen management team is about average.
Management Team

Jim Schoeneck

TITLE
Chairman of the Board
COMPENSATION
$476K
AGE
61
TENURE
0.2 yrs

Pat Cotroneo

TITLE
Senior VP of Finance & CFO
COMPENSATION
$4M
AGE
55
TENURE
12.3 yrs

K. Yu

TITLE
Chief Medical Officer
COMPENSATION
$5M
AGE
57
TENURE
4 yrs

Enrique Conterno

TITLE
CEO & Director
AGE
52
TENURE
0.3 yrs

Barry Berkowitz

TITLE
TENURE
25.3 yrs

Mike Martinelli

TITLE
Senior Vice President of Technical Development
TENURE
8.6 yrs

Karen Bergman

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
3.6 yrs

Michael Lowenstein

TITLE
Chief Legal Officer
TENURE
4 yrs

Richard Farley

TITLE
Vice President of Human Resources
AGE
62
TENURE
4.6 yrs

Leanne Price

TITLE
Chief Intellectual Property Officer
TENURE
4 yrs
Board of Directors Tenure

Average tenure and age of the FibroGen board of directors in years:

4.7
Average Tenure
66
Average Age
  • The tenure for the FibroGen board of directors is about average.
Board of Directors

Enrique Conterno

TITLE
CEO & Director
AGE
52
TENURE
0.3 yrs

George Martin

TITLE
Chairman of Scientific Advisory Board

Jim Schoeneck

TITLE
Chairman of the Board
COMPENSATION
$476K
AGE
61
TENURE
0.3 yrs

Thomas Kearns

TITLE
Lead Independent Director
COMPENSATION
$488K
AGE
82
TENURE
2.8 yrs

Jeff Henderson

TITLE
Independent Director
COMPENSATION
$455K
AGE
54
TENURE
4.7 yrs

Jeff Edwards

TITLE
Independent Director
COMPENSATION
$470K
AGE
58
TENURE
4.5 yrs

Kalevi Kurkijärvi

TITLE
Independent Director
COMPENSATION
$460K
AGE
67
TENURE
23.4 yrs

Rory Riggs

TITLE
Independent Director
COMPENSATION
$463K
AGE
66
TENURE
26.5 yrs

Toshinari Tamura

TITLE
Independent Director
COMPENSATION
$455K
AGE
75
TENURE
11.6 yrs

Roberto Rosenkranz

TITLE
Independent Director
COMPENSATION
$455K
AGE
69
TENURE
10 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess FibroGen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. FibroGen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1FG News

Simply Wall St News

1FG Company Info

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Details
Name: FibroGen, Inc.
1FG
Exchange: DB
Founded: 1993
$2,756,944,451
87,999,804
Website: http://www.fibrogen.com
Address: FibroGen, Inc.
409 Illinois Street,
San Francisco,
California, 94158,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FGEN Common Stock Nasdaq Global Select US USD 14. Nov 2014
DB 1FG Common Stock Deutsche Boerse AG DE EUR 14. Nov 2014
LSE 0IL8 Common Stock London Stock Exchange GB USD 14. Nov 2014
BRSE 1FG Common Stock Berne Stock Exchange CH CHF 14. Nov 2014
BMV FGEN * Common Stock Bolsa Mexicana de Valores MX MXN 14. Nov 2014
Number of employees
Current staff
Staff numbers
531
FibroGen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:34
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.